Information Provided By:
Fly News Breaks for January 8, 2020
ARNA
Jan 8, 2020 | 06:34 EDT
JMP Securities analyst Jason Butler reiterated an Outperform rating and $79 price target on Arena Pharmaceuticals after the company provided an update on its corporate outlook for 2020 and beyond, with the highlights being plans for eight Phase 2 and 3 readouts by year-end 2021 and at least one new IND each year through 2024. In a research note to investors, Butler says he believes the company remains well funded and has the right management team in place to execute on the expanding opportunity set.
News For ARNA From the Last 2 Days
There are no results for your query ARNA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.